Breast cancer is the most common oncological disease, which is equally common throughout the world. According to statistics of the World Health Organization, breast cancer accounts for more than 10% of all cancers in the world. The prognosis of WHO specialists is disappointing. In connection with the intensive growth in the number of people on the planet and the human lifespan, the incidence will increase steadily.
When choosing this or that method of therapy, the doctor needs to assess the quality of life of the patient during and after treatment. Unfortunately, traditional chemo- and radiotherapy has severe side effects on various body systems. Given the negative health consequences of such treatment, scientists and physicians are making efforts to find milder, but at the same time effective ways of treating breast cancer.
Relatively gentle treatment of breast cancer is hormonal therapy. The essence of the treatment is reduced to the suppression of the synthesis of female sex hormones (estrogens), or to the blockage of specific estrogen receptors. The thing is, female sex hormones can become the main carcinogenic factors in the development of cancer (hormone-dependent cancer) of the breast. Interacting with the receptors of cells, they trigger a chain of reactions during which the tumor cells begin to multiply actively.
Over the past few years, modern oncology uses drugs of a new generation based on fulvestrant substance. It is the representative of a new class of antiestrogenic drugs, which has a retarding effect on the proliferative properties of estrogens.
The mechanism of action of drugs based on fulvestrant is associated with direct effects on the receptors of estrogens located on the surface of tumor cells. Fulvestrant attaches itself to these receptors and blocks them. Thus, female sex hormones (estrogens) are no longer able to affect the tumor cell. Unable to reproduce, the tumor cell dies.